Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | POLE A456P |
Therapy | Pembrolizumab |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
POLE A456P | colorectal cancer | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a retrospective study, treatment with immune checkpoint inhibitors resulted in an overall response rate of 89% (22/29) and a disease control rate of 92% in metastatic colorectal cancer patients harboring pathogenic POLE/POLD1 variants, including a partial response in a patient harboring POLE A456P treated with Keytruda (pembrolizumab) (PMID: 38777726). | 38777726 |
PubMed Id | Reference Title | Details |
---|---|---|
(38777726) | Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. | Full reference... |